Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms
Passage Bio (PASG) reported a Q2 2026 net loss of $7.8 million and a six-month net loss of $15.4 million, with cash and cash equivalents declining to $24.2 million. The company disclosed substantial doubt about its ability to continue as a going concern without …